Skip to main content
. 2018 Jan 5;13(1):e0188212. doi: 10.1371/journal.pone.0188212

Fig 8.

Fig 8

Treatment of compounds 5 in both parkin-null (A and B) and mutant LRRK2 G2019S-expressing (C and D) flies. A: Climbing score of untreated and compound 5 (50 μM)-treated parkin-null flies (where 100% is the climbing score of normal flies). B: DA neuronal count (PPL1 cluster) of normal flies (control), parkin-null flies, and compound 5 (50 μM)-treated parkin-null flies. C: As in A, except that parkin-null flies were substituted with LRRK2 G2019S-expressing flies (the control is represented by the mutant flies). Two concentrations, 50 μM and 100 μM, of compound 5 were tested. D: As in B, except that parkin-null flies were substituted with LRRK2 G2019S-expressing flies. (*p < 0.05, **p < 0.01).